Risedronic acid
- Generic Name
- Risedronic acid
- Brand Names
- Actonel, Atelvia
- Drug Type
- Small Molecule
- Chemical Formula
- C7H11NO7P2
- CAS Number
- 105462-24-6
- Unique Ingredient Identifier
- KM2Z91756Z
- Background
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease
- Associated Therapies
- -
Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Hospital Regional 1o de Octubre
- Target Recruit Count
- 33
- Registration Number
- NCT05346419
- Locations
- 🇲🇽
Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE, Mexico City, Mexico
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT04922333
- Locations
- 🇺🇸
Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
Replication of the VERO Osteoporosis Trial in Healthcare Claims Data
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 12757
- Registration Number
- NCT04879420
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 84
- Registration Number
- NCT03861091
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸High Point Regional Medical Center, High Point, North Carolina, United States
Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?
- Conditions
- Interventions
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Sheffield Children's NHS Foundation Trust
- Target Recruit Count
- 13
- Registration Number
- NCT03208582
- Locations
- 🇬🇧
Clinical Research Facility, Sheffield, South Yorkshire, United Kingdom
Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 3
- Registration Number
- NCT02744482
- Locations
- 🇫🇷
CHU Limoges, Limoges, France
Heartland Osteoporosis Prevention Study
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 276
- Registration Number
- NCT02186600
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 86
- Registration Number
- NCT02148848
- Locations
- 🇹🇭
Siriraj Hospital, Bangkoknoi, Bangkok, Thailand
Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 79
- Registration Number
- NCT01950169
- Locations
- 🇸🇪
Department of Geriatric Medicine R94, Karolinska University Hospital, Stockholm, Sweden
Post-menopausal Women Osteoporosis(Phase III)
- Conditions
- Interventions
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT01806792
- Locations
- 🇰🇷
Chung-ang university hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.